Low-dose IL-2 studies and trials conducted to date in SLE were limited in patient numbers, and therefore it is not possible to accurately measure the specific impact of low-dose IL-2 or the non-specific concurrent immunosuppression on the management of the disease symptoms. This evidence concerns the gene IL2 and systemic lupus erythematosus.